Strategic Partnerships Temedica has a history of collaboration with major pharma players, including a Bristol Myers Squibb partnership to develop digital health solutions. This suggests a receptive environment for co-developed digital companion apps and real-world data initiatives that can be expanded with new pharma partners.

Diabetes Focus The launch of Dibi, a digital companion app for Type 2 diabetes patients sponsored by Novo Nordisk, indicates strong interest and capability in chronic disease management solutions. This creates a sales path for risk management programs, patient engagement platforms, and real-world evidence generation for diabetes therapies.

Data Platform Value With the Permea data platform introduced in 2022 and a revenue model in the low to mid seven-figure potential, Temedica can position its data infrastructure as a backbone for pharma’s go-to-market analytics, real-world insights, and AI-driven brand performance tuning for multiple therapeutic areas.

Leadership & Expertise Adding expert advisor Markus Leyck Dieken, a former Gematik CEO, signals enhanced credibility in digital health interoperability and regulatory considerations. This presents an opportunity to engage customers seeking compliant, scalable digital solutions and strategic guidance.

Growth & Financing With a $45M funding backdrop and a growing employee base, Temedica is positioned to scale offerings, accelerate go-to-market efforts, and expand across additional disease areas. This supports multi-year collaborations, expanding from psoriasis and diabetes into broader real-world evidence programs and AI-enabled marketing solutions.